Latest News
Vogenx, Inc.
- Vogenx Launches Phase 2b EMERGE Trial of Oral Mizagliflozin for Post-Bariatric Hypoglycemia
- Why is Vogenx stock climbing 6% today? By Investing.com
- Vogenx initiates phase 2b trial for post-bariatric hypoglycemia By Investing.com
- People on the Move: Richard Gorman Joins Vogenx as Chief Commercial Officer
- Richard Gorman Resigns from Vogenx Board to Assume Chief Commercial Officer Position
- Vogenx, Inc. Appoints Board Member Richard Gorman as Chief Commercial Officer, Effective October 12, 2026
- Vogenx Appoints Richard Gorman Chief Commercial Officer to Advance Mizagliflozin Strategy
- Vogenx, Inc. (VOGX) Appoints Richard Gorman as Chief Commercial Officer
- Vogenx appoints Richard Gorman as chief commercial officer
- Form 4 Vogenx For: 7 October By Investing.com
- 155,000 options for Vogenx (VOGX) science chief vest over three years, subject to continued service.
- Vogenx Appoints Ken Toombs to Board of Directors
Headlines from the last 30 days, linking to the original publishers. See all market news →